| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
IC50: 0.3 nM (FASN)[1]
|
|---|---|
| ln Vitro |
In cellular occupancy experiments, IPI-9119 inhibits FASN with an IC50 of about 10 nM. It also exhibits selectivity against various other serine hydrolases that is greater than 400-fold[2]. IPI-9119 (0.1-0.5 μM; 6 days) causes cell cycle arrest and apoptosis in addition to inhibiting cell growth[1]. IPI-9119 (0.05-5 μM; 6 days) suppresses the expression of the AR-FL and AR-V7 proteins[1].
|
| ln Vivo |
In animal models with CRPC xenografts, IPI-9119 (SC pump infusion; 0.5 μL/h; 100 mg/mL; for 28 days) suppresses the formation of tumors[1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: Prostate cancer (PCa) cells ( AD LNCaP, AI C4-2, LNCaP-95 and 22Rv1 AI cells) Tested Concentrations: 0.1, 0.5 μM Incubation Duration: 6 days Experimental Results: Inhibited PCa cell growth. Had no growth inhibition in FASN KO PCa cells. Cell Cycle Analysis[1] Cell Types: PCa cells Tested Concentrations: 0.1, 0.5 μM Incubation Duration: 6 days Experimental Results: diminished the proportion of S-phase cells and increased that of G0/G1-, sub-G1–phase cells and diminished expression of cyclin A2. Western Blot Analysis[1] Cell Types: PCa cells Tested Concentrations: 0.05, 0.1, 0.25, 0.5, 5 μM Incubation Duration: 6 days Experimental Results: Dramatically diminished AR-FL protein levels in AD LNCaP, AI C4-2 cells (expressing only AR-FL ) and diminished the expression of AR-V7 in LNCaP-95, 22Rv1 AI cells driven by this variant. |
| Animal Protocol |
Animal/Disease Models: 8-10-week male Ncr Nu Castrated mice or castrated NOD male SCID with 22Rv1 or LNCaP-95 cells[1]
Doses: 100 mg/mL Route of Administration: SC pump infusion (0.5 μL/h; 100 mg/mL); for 28 days Experimental Results: Inhibited tumor growth of castration-resistant prostate cancer ( CRPC) xenografts mouse models. |
| References |
|
| Molecular Formula |
C24H19F2N5O5
|
|---|---|
| Molecular Weight |
495.434972047806
|
| Exact Mass |
495.135
|
| CAS # |
1346564-56-4
|
| PubChem CID |
68208572
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
36
|
| Complexity |
845
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1C=CC=C(C=1N1C(N(C(N(C2=CC=C(C(=O)O)C=C2OC2C=CC=CC=2)C(C)C)=O)N=N1)=O)F
|
| InChi Key |
VYXOFKWKPKVNID-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H19F2N5O5/c1-14(2)29(19-12-11-15(22(32)33)13-20(19)36-16-7-4-3-5-8-16)23(34)31-24(35)30(27-28-31)21-17(25)9-6-10-18(21)26/h3-14H,1-2H3,(H,32,33)
|
| Chemical Name |
4-[[4-(2,6-difluorophenyl)-5-oxotetrazole-1-carbonyl]-propan-2-ylamino]-3-phenoxybenzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (201.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0184 mL | 10.0920 mL | 20.1841 mL | |
| 5 mM | 0.4037 mL | 2.0184 mL | 4.0368 mL | |
| 10 mM | 0.2018 mL | 1.0092 mL | 2.0184 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
